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Abstract
Background: The scaffold attachment factor B1 and B2 genes, SAFB1/SAFB2 (both located on
chromosome 19p13.3) have recently been suggested as tumour suppressor genes involved in
breast cancer development. The assumption was based on functional properties of the two genes
and loss of heterozygosity of intragenic markers in breast tumours further strengthened the
postulated hypothesis. In addition, linkage studies in Swedish breast cancer families also indicate the
presence of a susceptibility gene for breast cancer at the 19p locus. Somatic mutations in SAFB1/
SAFB2 have been detected in breast tumours, but to our knowledge no studies on germline
mutations have been reported. In this study we investigated the possible involvement of SAFB1/
SAFB2 on familiar breast cancer by inherited mutations in either of the two genes.
Results: Mutation analysis in families showing linkage to the SAFB1/2 locus was performed by DNA
sequencing. The complete coding sequence of the two genes SAFB1 and SAFB2 was analyzed in
germline DNA from 31 affected women. No missense or frameshift mutations were detected. One
polymorphism was found in SAFB1 and eight polymorphisms were detected in SAFB2. MLPA-anlysis
showed that both alleles of the two genes were preserved which excludes gene inactivation by large
deletions.
Conclusion: SAFB1 and SAFB2 are not likely to be causative of the hereditary breast cancer
syndrome in west Swedish breast cancer families.
Background
Breast cancer is the second most frequent cancer among
women in the world. According to the Swedish Cancer
Society 1,3 million women are estimated to develop
breast cancer and the mortality rate was 36% in 2007. In
5–10% of all cases, an inherited susceptibility for breast
cancer is predisposing women to develop the disease. Sev-
eral genes have been identified as tumour suppressor
genes that increase the overall risk to be affected by breast
cancer. The two highly penetrant genes BRCA1  and
BRCA2 are responsible for 25–40% of the familial cases
depending on population. Other genes are causing rare
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cancer syndromes and are associated with an increased
risk of breast cancer such as TP53, PTEN, STK11/LKB1,
TWIST1 [1-4]. However, these genes have not yet proved
causative in families with no other manifestations than
breast cancer and there are probably other yet unknown
tumour suppressor genes involved in breast tumorigene-
sis [5-7]. Large multi-center association studies have
recently identified risk alleles of specific SNPs (single
nucleotide polymorphism) as being associated with an
increased risk of breast cancer [8,9]. A proportion of the
familial cases may be explained by inheritance of several
interacting low risk alleles. Nevertheless, there are multi-
ple case families negative for BRCA1 and BRCA2 muta-
tions with an inheritance mode that clearly appears as
dominant and monogenic. In these families interacting
low penetrant risk alleles therefore seem less likely to be
the cause of the inherited predisposition. Recent linkage
analyses performed by our group on Swedish families
with hereditary breast cancer showed suggestive linkage to
chromosome 10q, 12q and 19p [10]. In all, 74 individuals
from 14 families, the majority originating from the west
Swedish region, were genotyped using high density SNP
microarrays. The identified linkage region at chromosome
19p (HLOD 2.1), overlapped with candidate regions
identified by other groups and the region has been sug-
gested to be the locus of a tumour suppressor gene
[11,12]. The two genes, SAFB1 [Genbank NM_002967.2]
and SAFB2 [Genbank NM_014649.2] are encoding scaf-
fold attachment factor binding proteins that are localized
in the nuclear matrix of the cell. Both genes are located at
chromosome 19p13.3 and a complete loss of Safb1/2 pro-
tein has been reported in 20% of breast tumours [13]. The
SAFB1/2 genes are coding for large proteins that have been
characterized as proteins with multiple functions that in
many ways are similar to functional properties of BRCA1
and  BRCA2. Oesterreich and co-workers showed that
Safb1 and Safb2-proteins function as transcriptional regu-
lators mediated by repression of the oestrogen receptor
which would point to a plausible role in carcinogenesis
[14,15]. The group followed up this study by performing
LOH analyses of 57 tumours (no reports on family his-
tory) with microsatellites in the 19p locus that harbours
the SAFB1/2 genes [11]. They found a markedly high frac-
tion of LOH in the marker D19S216 with 29 of 37 (78%)
informative DNA samples with allelic deletion. Deletions
in the same 19p region has also been reported in an earlier
study by Lindblom et al. [12] in which 27% of the studied
tumours (n = 82) showed LOH in this chromosomal
region. We wanted to investigate whether SAFB1  and
SAFB2 genes may be causative of hereditary breast cancer
by analyzing patients with familiar breast cancer for inher-
ited mutations in SAFB1 and SAFB2. To our knowledge,
this is the first germline mutation analysis of the supposed
tumour suppressor genes SAFB1 and SAFB2.
Methods
Patients
Germline DNA was extracted from venous blood, sam-
pled from 31 affected women in 14 families with multiple
cases of breast cancer and used as template in the germline
mutation screening of the SAFB1 and the SAFB2 genes.
Index cases have been analyzed and found negative for
BRCA1  and  BRCA2  mutations. Clinical characteristics
such as age of onset, ovarian cancer occurrence etc. are
presented in our previous publication [10]. Linkage anal-
ysis on affected women and relatives in the 14 families
have previously shown positive linkage (HLOD 2.1) to
the chromosomal region 19p13.3-q12, within which the
SAFB1 and SAFB2 genes are located [10]. Two or three
affected women from each family (n = 31) were included
in the DNA sequence analyses of SAFB1/2 genes. One case
from each family (n = 14) was included in the MLPA anal-
ysis. All patients in the study have given a written
informed consent to participate in the study and the study
was reviewed and approved by the University hospital
ethic's committee, reference Ö-447-02.
Polymerase chain reaction, PCR
The genomic structures of the SAFB1 and SAFB2 genes are
very similar. The coding sequences of the two genes are
distributed over 21 exons, spanning 45 kb and 36 kb
respectively. The genes are ordered in a bidirectional, head
to head state with a probable shared promoter [15].
SAFB1  and  SAFB2  encode proteins with 915 and 953
amino acids respectively. The twenty-one exons (with
flanking sequences) of SAFB1 and SAFB2 were amplified
by PCR, primer sequences and PCR conditions are availa-
ble in Additional file 1. PCR reactions were carried out in
20 μl volumes according to standard protocol. All reac-
tions were run by touch-down PCR, in which the anneal-
ing temperature was gradually decreased during the ten
first cycles to then continue the last 15 cycles at the lower
annealing temperature.
DNA sequencing
The PCR products were purified by magnetic beads
(AMPure, Beckman-Coulter, http://www.beckmancoul
ter.com) and used as template in cycle sequencing reac-
tions for analyses of sense and antisense strands. Diluted
forward and reverse PCR primers were used as sequencing
primers. The Big Dye Terminator chemistry 3.1 was used
and reactions were carried out as recommended by the
commercial supplier (Applied Biosystems, Foster city,
USA). The sequence reaction products were analyzed on
the Genetic Analyzer ABI3730 and the ABI3130 (Applied
Biosystems). Sequencing analyses and comparisons to a
reference sequence (SAFB1  NM_ 002967, SAFB2
NM_014649) was performed using the Seqscape software
(Applied Biosystems).BMC Medical Genetics 2008, 9:108 http://www.biomedcentral.com/1471-2350/9/108
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Multiplex ligation-dependent probe amplification, MLPA 
analysis
A screen for large deletions or amplifications over SAFB1
and SAFB2 genes was performed by Multiplex Ligation-
dependent Probe Amplification, MLPA. Five probes
hybridizing to SAFB1  and two probes for SAFB2  were
designed, see Table 1. The reference probe-mix P300 and
reaction buffers were supplied by MRC-Holland (Amster-
dam, NL) and the MLPA reactions were performed accord-
ing to the manufacturer's recommendations. The
amplified fragments were separated on an ABI 3130
Genetic Analyzer (Applied Biosystems) using Genescan-
ROX 500 size standards (Applied Biosystems). Fragment
analysis was performed with the Gene Mapper software
(Applied Biosystems). Analysis of genomic deletions and
duplications was based on the comparison of the peak
areas of PCR-fragments generated from test samples and
corresponding peak areas generated from control DNA
samples. Normalizations of the peak areas were carried
out according to the manufacturer's protocol.
Results
In order to investigate the potential role for SAFB1/2 as
tumour suppressor genes involved in familial breast can-
cer, we performed a mutation screening of the two genes
in families that display genetic linkage to the 19p locus.
The complete coding sequence was analyzed by direct
DNA sequencing. No frameshift or missense mutations
were detected in any of the 31 analyzed DNA samples.
One silent polymorphism was detected in the coding
sequence of SAFB1. Three polymorphisms were detected
in coding sequence of SAFB2, and further five polymor-
phisms in exon-flanking intronic sequence. All three cod-
ing polymorphisms were previously annotated in the SNP
database, see Table 2. All sequence variations were ana-
lysed for aberrant splicing by submission of the altered
sequence to the splice site prediction database BDGP (Ber-
kely Drosophila Genome Project, http://www.fruit
fly.org). One of the variants generated high score predic-
tions of a novel splice donor site. The SNP was located in
the 3' UTR-sequence, downstream of the termination
codon, which makes it less likely that it affects the protein.
As the allele does not segregate with disease we do not
believe that the variant is pathogenic in a way that it
would be affecting cancer susceptibility. Normalized
ratios of case/control peak areas from the MPLA analysis
showed no indications of deletions and the genes are not
likely to be inactivated by entire gene deletions or by dele-
tions of the targeted exons, see Fig. 1.
Discussion
Many genes have been suggested as genes predisposing for
breast cancer. Since the discovery of BRCA1 and BRCA2,
numerous genes have been associated with a moderate
increase in risk and are thought to interact in a polygenic
inheritance mode to increase the susceptibility for breast
cancer. Attempts to identify further high penetrant genes
such as BRCA1 and BRCA2 have not been successful and
most of the research has now been directed towards iden-
tifying low risk alleles. However, there are families with
multiple cases of breast cancer that present a pedigree with
an undisputable dominant inheritance mode for which a
polygenic model would not be appropriate. Several small
and large linkage studies have failed to generate strong
evidence for a susceptibility locus [16-18] and it seems
likely that heterogeneity among families is a major obsta-
cle when identifying genes with linkage studies.
Our previously reported linkage locus at 19p [10] overlaps
with earlier identified chromosomal regions with fre-
quent LOH in breast tumours [11,12]. Due to these find-
ings the 19p-region appears as a reasonable candidate
region for a tumour suppressor gene. One of the many
functions attributed to SAFB1  and  SAFB2  is that of a
Table 1: Hybridization sequences of MLPA probes.
Probe Gene/exon Amplicon size (bp) Hybridization sequence LPO* Hybridization sequence RPO**
1 SAFB1 exon 16 96 TACCATTCTGACTTTAACCGCCAGGACC GCTTCCACGACTTTGACCACAGGGAC
























Amplicon size includes length of universal MLPA primer sequences.
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repressor of the estrogen receptor α, ERα, [13,15,19]. One
could speculate that an inherited mutation in SAFB1 or
SAFB2 followed by a somatic mutation later in life would
lead to a complete gene inactivation and a disturbed reg-
ulation of ERα. Due to the many downstream targets of
ER regulation [20], a lost repression of ERα would proba-
bly lead to an overexpression of a number of genes
involved in growth and development. Somatic mutations
of SAFB1 and SAFB2 have previously been observed in
tumour DNA [11], but to our knowledge this is the first
study of germline DNA from patients with hereditary
breast cancer. Altogether, we identified eight polymor-
phisms in SAFB2 and one in SAFB1. None of the altera-
tions caused an amino acid exchange which makes them
less likely to be seriously affecting the functioning proper-
ties of the proteins. All but one alteration (SAFB1 exon 8)
were found in regions with low degree of conservation
which adds to the assumption that the variants have little
or no effect on the resulting protein. Mutation analysis by
DNA sequencing may fail to detect large genomic altera-
The normalized values of peak areas for each probe's hybridization is given as the ratio of case/control, here shown for SAFB  probes Figure 1
The normalized values of peak areas for each probe's hybridization is given as the ratio of case/control, here 
shown for SAFB probes. All probes have a case/ctrl ratio of approximately 1,0 which indicate that both alleles are preserved 
in the genome. Probe coverage in SAFB1/2 genes are shown below the graph, exon/intron sizes are not true to scale. Probe 
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Table 2: Polymorphisms in SAFB1 and SAFB2 in 31 patients (62 alleles).
Gene Exon/Intron Nucleotide position Change Frequency of minor allele SNP annotation
SAFB1 exon 8 c.1155 CCC>CCT Asp<Asp 1/62 NA*
SAFB2 exon 4 c.459 GAC>GAT Asp>Asp 1/62 NA*
exon 9 c.1257 CGC>CGT Arg>Arg 3/62 rs806706
intron 9 c.1296+31 T>C 1/62 NA*
intron 13 c.1782+3 G>A 1/62 NA*
intron 14 c.1919+18 A>G 42/62 rs10413286
exon 16 c.2337 CAC>CAT His>His 4/62 NA*
intron 17 c.2394+24 C>T 10/62 rs2285963
3' UTR c.2862+14 C>T 4/62 NA*
SNP annotations refer to NCBI SNPdb build 126.
*NA, Not Annotated.BMC Medical Genetics 2008, 9:108 http://www.biomedcentral.com/1471-2350/9/108
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tions such as entire or partial gene deletions. To address
this issue we analysed the genes by MLPA analysis which
is a suitable method for the detection of deletions or
duplications. As no MLPA-probes were commercially
available for the SAFB1/2  genes we developed and
designed probes that hybridize to seven exons in SAFB1
and SAFB2. The probes used in the assay are spread over
the genomic sequence of the two genes and an entire gene
deletion or deletion of a targeted exon would have been
detected as a reduction in peak area in the fragment anal-
ysis, see Fig 1.
The study has been restricted to mutation and deletion
analysis of the coding sequence and there is of course the
possibility of epigenetic or other less apparent alterations
in the genes. There is also the risk of another tumour sup-
pressor gene located in the close vicinity of SAFB1 and
SAFB2 that would be the true basis for the observed link-
age to the region. Another gene in the 19p-region that may
appear as a suitable candidate is the STK11/LKB1 gene
that is associated with the Peutz-Jehger's syndrome, in
which breast cancer is a frequent manifestation. However,
the hypothesis that the STK11/LKB1 gene is causative of
familial breast cancer syndrome has already been tested
by germline mutaion screening in Swedish breast cancer
families [5]. As the families in that study were of similar
origin as the families in the present study we find it
unlikely that the STK11/LKB1 gene is the source of the 19p
linkage.
Conclusion
In conclusion, this study did not reveal any pathogenic
germline mutations and no apparent genomic deletions
in SAFB1 or SAFB2, and the hypothesis that the two genes
would function as tumour suppressor genes could not be
verified in this patient based material. The SAFB1/2 genes
are not likely to confer a strong influence on familiar
breast cancer in the west Swedish population.
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